Skip to main content
Log in

Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis

Advances in Therapy Aims and scope Submit manuscript

Abstract

Bisphosphonates are effective agents for postmenopausal osteoporosis, but their efficacy in patients with type 2 diabetes mellitus (DM) is not known. The investigators evaluated bone mineral density (BMD) response to alendronate in women with concurrent late postmenopausal osteoporosis and type 2 DM. In a retrospective, matched case-control study, 26 late postmenopausal osteoporotic women with type 2 DM (age, 67.6±7.3 y; type 2 DM duration, 12.8±6.8 y; duration of menopause, 10.9±7.4 y; time on alendronate: 4.8±2.3 y; body mass index [BMI], 31.4±6.3 kg/m2) were matched with 26 controls according to age, BMI, duration of menopause, and alendronate treatment received. All subjects were given alendronate 10 mg/d or 70 mg/wk, along with sufficient vitamin D (≥400 IU) and calcium (≥1 g/d) intake, for 4.8 y. Response to alendronate therapy was determined by assessment of mean percent change in BMD of total hip, femoral neck, forearm, and lateral spine. The presence of type 2 DM resulted in no difference in spinal BMD response to alendronate therapy. In contrast, BMD in the total hip (mean percent change in BMD, −5.6% vs +1.4%;P=.096), femoral neck (−8.1 % vs +1.1 %;P=.015), and forearm (−3.6% vs +12.7%;P=.013) fell progressively from baseline in subjects with type 2 DM who were taking alendronate for 4.8 y, compared with controls. Elderly, postmenopausal, osteoporotic obese women with type 2 DM are resistant to long-term bisphosphonates, especially in regions of the hip, femoral neck, and forearm compared with the spine. The efficacy of bone resorption inhibitors in patients with type 2 DM, especially in comparison with anabolic agents, should be considered in additional studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stein E, Shane E. Secondary osteoporosis.Endocrinol Metab Clin North Am. 2003;32:115–134.

    Article  PubMed  Google Scholar 

  2. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress.Bone. 2007;40:1408–1414.

    Article  PubMed  CAS  Google Scholar 

  3. Kahn SE, Haffner SM, Heise MA, et al, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N Engl J Med. 2006;355:2427–2443.

    Article  PubMed  CAS  Google Scholar 

  4. Keegan THM, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL, The fracture intervention trial. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the Fracture Intervention Trial.Diabetes Care. 2004;27:1547–1553.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Selcuk Dagdelen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dagdelen, S., Sener, D. & Bayraktar, M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Therapy 24, 1314–1320 (2007). https://doi.org/10.1007/BF02877778

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02877778

Keywords

Navigation